Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?
Executive Summary
Human Genome Sciences' Phase III breakthrough with the biologic Benlysta in lupus has renewed hope in new drugs for a difficult-to-treat disease. The question now, though, is how big can the market grow for this elusive condition, given the high unmet need